scholarly journals Long-term use of proton pump inhibitors and prevalence of disease- and drug-related reasons for gastroprotection-a cross-sectional population-based study

2016 ◽  
Vol 26 (1) ◽  
pp. 9-16 ◽  
Author(s):  
Susanna M. Wallerstedt ◽  
Johan Fastbom ◽  
Johannes Linke ◽  
Sigurd Vitols
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Population Based ◽  
Cross Sectional ◽  
Population Based Study

Long-Term Use of Proton Pump Inhibitors and Risk of Gastric Cancer Development after Treatment for H. Pylori : A Population-Based Study

2017 ◽  
Vol 152 (5) ◽  
pp. S833
Author(s):  
Michael K. Cheung ◽  
Angel Y. Wong ◽  
Lijia Chen ◽  
Esther W. Chan ◽  
Ian C. Wong ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Population Based ◽  
Cancer Development ◽  
Population Based Study ◽  
H Pylori

Use of proton pump inhibitors and risk of rosacea: A nationwide population‐based study

2020 ◽  
Vol 47 (10) ◽  
pp. 1126-1130
Author(s):  
Ying‐Xiu Dai ◽  
Ying‐Hsuan Tai ◽  
Chih‐Chiang Chen ◽  
Yun‐Ting Chang ◽  
Tzeng‐Ji Chen ◽  
...  
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Population Based ◽  
Population Based Study

scholarly journals Hypomagnesemia Induced by Long-Term Treatment with Proton-Pump Inhibitors

2015 ◽  
Vol 2015 ◽  
pp. 1-7 ◽  
Author(s):  
Simone Janett ◽  
Pietro Camozzi ◽  
Gabriëlla G. A. M. Peeters ◽  
Sebastiano A. G. Lava ◽  
Giacomo D. Simonetti ◽  
...  
Keyword(s):  
Receptor Antagonist ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Term Treatment ◽  
Cross Sectional ◽  
Magnesium Metabolism ◽  
Poor Renal Function ◽  
Long Term Treatment

In 2006, hypomagnesemia was first described as a complication of proton-pump inhibitors. To address this issue, we systematically reviewed the literature. Hypomagnesemia, mostly associated with hypocalcemic hypoparathyroidism and hypokalemia, was reported in 64 individuals on long-term proton-pump inhibitors. Hypomagnesemia recurred following replacement of one proton-pump inhibitor with another but not with a histamine type-2 receptor antagonist. The association between proton-pump inhibitors and magnesium metabolism was addressed in 14 case-control, cross-sectional studies. An association was found in 11 of them: 6 reports found that the use of proton-pump inhibitors is associated per se with a tendency towards hypomagnesemia, 2 found that this tendency is more pronounced in patients concurrently treated with diuretics, carboplatin, or cisplatin, and 2 found a relevant tendency to hypomagnesemia in patients with poor renal function. Finally, findings likely reflecting decreased intestinal magnesium uptake were observed on treatment with proton-pump inhibitors. Three studies did not disclose any relationship between magnesium metabolism and treatment with histamine type-2 receptor antagonists. In conclusion, proton-pump inhibitors may cause hypomagnesemia. In these cases, switching to a histamine type-2 receptor antagonist is advised.

Proton Pump Inhibitors, Irritable Bowel Syndrome and Functional Dyspepsia - A Random Population Based Study

2017 ◽  
Vol 152 (5) ◽  
pp. S717
Author(s):  
Natasha A. Koloski ◽  
Michael P. Jones ◽  
Marjorie M. Walker ◽  
Alkesh V. Zala ◽  
Martin Veysey ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Functional Dyspepsia ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Population Based ◽  
Population Based Study ◽  
Irritable Bowel
Sign in / Sign up

Export Citation Format

Share Document